ClinicalTrials.gg
CompletedNCT02552121Updated Apr 8, 2021Results posted

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

A Phase 1/2 interventional study of Tisotumab vedotin (HuMax-TF-ADC) in Ovary Cancer, Cervix Cancer and Endometrium Cancer, sponsored by Seagen Inc.. Completed at 16 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Ovarian Neoplasms by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Ovarian Neoplasms · Pfizer.

Enrollment
22nd of 38
33 · median 52
Started
2015
with 1 other
Phase 1/2
4 of 38
none open now
Registered
9th of 38
by date

Among the 38 studies in Ovarian Neoplasms by Pfizer, this one is the 22nd largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 1/2, and was the 9th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 38 studies in Ovarian Neoplasms by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Ovarian Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.

Read the detailed description

The study is conducted in two parts. In the Dose Escalation portion of the trial, subjects are enrolled into cohorts at increasing dose levels of tisotumab vedotin (HuMax-TF-ADC) in 28 day treatment cycles.

The Cohort Expansion portion of the trial will further explore the recommended phase 2 dose of tisotumab vedotin (HuMax-TF-ADC) as determined in Part 1.

03

Conditions studied

  • Ovary Cancer
  • Cervix Cancer
  • Endometrium Cancer
  • Bladder Cancer
  • Prostate Cancer (CRPC)
  • Esophagus Cancer
  • Lung Cancer (NSCLC)

Keywords

  • ovary cancer
  • cervix cancer
  • endometrium cancer
  • bladder cancer
  • prostate cancer (CRPC)
  • esophagus cancer
  • lung cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with , advanced and/or cancer who have failed available standard treatments or who are not candidates for standard therapy.

Patients must have according to v1.1

  • Age ≥ 18 years.
  • Acceptable renal function.
  • Acceptable liver function.
  • Acceptable hematological status (hematologic support allowed under certain circumstances).
  • Acceptable coagulation status.
  • Have an (ECOG) performance status of 0 or 1.
  • of at least three months.
  • A negative serum pregnancy test (if female and aged between 18-55 years old).
  • Women who are pregnant or breast feeding are not to be included.
  • Patients, both females and males, of must agree to use adequate during and for six months after the last infusion of HuMax-TF-ADC.
  • Following receipt of verbal and written information about the study, patients must provide signed before any study-related activity is carried out.

Exclusion criteria

Exclusion Criteria:

  • Known past or current coagulation defects.
  • Diffuse alveolar hemorrhage from vasculitis.
  • Known bleeding diathesis.
  • Ongoing major bleeding.
  • Trauma with increased risk of life-threatening bleeding.
  • Have cardiac disease.
  • A baseline as corrected by Fridericia's formula (QTcF) > 450 msec, a complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left bundle branch block form) or an incomplete left bundle branch block.
  • Therapeutic anti-coagulative or long term anti- treatment except use of low dose acetylsalicylic acid (ASA) up to 81 mg/day and non-ASA nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support within one week or pegylated G-CSF within two weeks before the Screening Visit.
  • Have received a cumulative dose of ≥ 150 mg (prednisone or equivalent doses of corticosteroids) within two weeks before the first infusion.
  • No dietary supplements allowed during the study period, except multivitamins, vitamin D and calcium.
  • Major surgery within six weeks or open within 14 days before drug infusion.
  • Plan for any major surgery during treatment period.
  • Patients not willing or able to have a pre-trial tumor biopsy taken (the screening biopsy can be omitted if archived material is available).
  • Presence or anticipated requirement of epidural catheter in relation to infusions (within 48 hours before and after dose of trial drug).
  • Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke.
  • Any anticancer therapy including; small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug within four weeks or five half lives, whichever is longest, before first infusion.
  • Prior treatment with bevacizumab within twelve weeks before the first infusion.
  • Prior therapy with a conjugated or unconjugated auristatin derivative.
  • Radiotherapy within 28 days prior to first dose.
  • Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.
  • Known past or current other than inclusion diagnosis, except for:
  • Cervical carcinoma of Stage 1B or less.
  • Non-invasive basal cell or squamous cell skin carcinoma.
  • Non-invasive, superficial bladder cancer.
  • Prostate cancer with a current PSA level \< 0.1 ng/mL.
  • Breast cancer in BRCA1 or BRACA2 positive ovarian cancer patients.
  • Any curable cancer with a complete response (CR) of > 5 years duration.
  • Radiographic evidence of cavitating pulmonary lesions and tumor adjacent to or invading any large blood vessel unless approved by sponsor.
  • Ongoing, significant , uncontrolled medical condition.
  • Presence of peripheral neuropathy.
  • Active viral, bacterial or fungal infection requiring intravenous treatment with antimicrobial therapy starting less than four weeks prior to first dose.
  • Oral treatment with antimicrobial therapy starting less than two weeks prior to first dose.
  • Known seropositivity.
  • Positive serology (unless due to vaccination or passive immunization due to Ig therapy) for .
  • Positive serology for based on test at screening.
  • Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.
  • Inflammatory lung disease including moderate and severe asthma and (COPD) requiring chronic medical therapy.
  • Ongoing acute or chronic inflammatory skin disease.
  • Active ocular surface disease at baseline (based on ophthalmological evaluation).
  • History of cicatricial conjunctivitis (as evaluated by an ophthalmologist).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Tisotumab vedotin (HuMax-TF-ADC)

    Drug: Tisotumab vedotin (HuMax-TF-ADC)

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants Who Experience at Least One Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks

  2. Part 2: Number of Participants Who Experience at Least One Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  3. Part 1: Number of Participants Who Experienced at Least One or More Serious Adverse Event (SAE)

    A SAE is defined as an AE that met one or more of the following criteria/outcomes which were classified as serious: Required inpatient hospitalization or prolongation of existing hospitalization. Resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. Was a congenital anomaly/birth defect. Medically important determined by the investigator. Resulted in death. Was life-threatening.

    Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks

  4. Part 2: Number of Participants Reporting One or More Serious Adverse Events (SAE)

    A SAE is defined as an AE that met one or more of the following criteria/outcomes which were classified as serious: Required inpatient hospitalization or prolongation of existing hospitalization. Resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. Was a congenital anomaly/birth defect. Medically important determined by the investigator. Resulted in death. Was life-threatening.

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  5. Part 1: Number of Participants Reporting One or More Infusion-related Adverse Events

    An infusion-related adverse event (AE) was defined as an AE occurring during infusion where the onset date and time of the event occurred within infusion time (+24 hours), and the event was judged as related to tisotumab vedotin by the investigator.

    Time frame: Day 1, Day 8 & Day 15 (+1 day) until end of treatment (Part 1), approximately 48 weeks

  6. Part 2: Number of Participants Reporting One or More Infusion-related Adverse Events

    An infusion-related adverse event (AE) was defined as an AE occurring during infusion where the onset date and time of the event occurred within infusion time (+24 hours), and the event was judged as related to tisotumab vedotin by the investigator.

    Time frame: Day 1, Day 8 & Day 15 (+1 day) until end of trial (Part 2), up to 36 weeks

  7. Part 1: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events

    A CTCAE AE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator.

    Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks

  8. Part 2: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events

    A CTCAE AE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator.

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  9. Part 1: Number of Participants Reporting One or More Treatment-related Adverse Events

    A treatment-related AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; which has a causal relationship with the treatment.

    Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks

  10. Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events

    A treatment-related AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; which has a causal relationship with the treatment.

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

Secondary outcomes

  1. Part 1: Number of Participants With Markedly Abnormal Laboratory Values

    The number of participants with any markedly abnormal standard safety laboratory values collected throughout study. Markedly abnormal laboratory values are defined as any grade \>=3 laboratory abnormality events.

    Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks

  2. Part 2: Number of Participants With Markedly Abnormal Laboratory Values

    The number of participants with any markedly abnormal standard safety laboratory values collected throughout study. Markedly abnormal laboratory values are defined as any grade \>=3 laboratory abnormality events.

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  3. Part 1: Number of Participants Who Experienced a Skin Rash

    Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks

  4. Part 2: Number of Participants Who Experienced a Skin Rash

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  5. Part 1: Number of Participants Who Experienced a Bleeding Event

    Time frame: Baseline to end of trial (Part 1), up to 72 weeks

  6. Part 2: Number of Participants Who Experienced a Bleeding Event

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  7. Part 1: Number of Participants Who Experienced a Neuropathy Event

    Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks

  8. Part 2: Number of Participants Who Experienced a Neuropathy Event

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  9. Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8 and 15, + 24 hours 1st infusion (Day 2), + 24 hours 3rd infusion (Day 16), + 72 hours 3rd infusion (Day 18), + 168 hours 3rd infusion (Day 22) of Cycle 1

  10. Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)

    Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

    Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1

  11. Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Tisotumab Vedotin (HuMax-TF-ADC)

    Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase.

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8 and 15, + 24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), +168 hours 3rd infusion (Day 22) of Cycle 1

  12. Part 1: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  13. Part 2: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)

    Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

    Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1

  14. Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  15. Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)

    Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

    Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1

  16. Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Tisotumab Vedotin (HuMax-TF-ADC)

    Data is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.

    Time frame: Before infusion of Day 1, 8 and 15 of Cycle 1

  17. Part 1: Terminal Phase Elimination Half-life (T1/2) for Tisotumab Vedotin (HuMax-TF-ADC)

    Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore t1/2 could not be determined.

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  18. Part 1: Total Clearance (CL) of Tisotumab Vedotin (HuMax-TF-ADC)

    Data is only available for Part 1, for Part 2 inadequate pharmacokinetic samples were collected after the third dose to define a terminal phase, and therefore CL could not be determined.

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  19. Part 1: Apparent Volume of Distribution (Vz) for Tisotumab Vedotin (HuMax-TF-ADC)

    Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore Vz could not be determined.

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  20. Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  21. Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)

    Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

    Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1

  22. Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Total HuMax-TF (Conjugated and Non-conjugated)

    Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase.

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  23. Part 1: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  24. Part 2: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)

    Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

    Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1

  25. Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  26. Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)

    Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

    Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1

  27. Part 1: Terminal Phase Elimination Half-life (T1/2) for Total HuMax-TF (Conjugated and Non-conjugated)

    Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore t1/2 could not be determined.

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  28. Part 1 and Part 2: Total Clearance (CL) of Total HuMax-TF (Conjugated and Non-conjugated)

    CL could not be estimated for Part 1 or Part 2 participants due to insufficient number of samples taken.

    Time frame: 0 to 2 hours post-dose on days 1, 8, 15, +24 hrs 1st infusion, +24 hrs 3rd infusion, +72 hrs 3rd infusion, +168 hrs 3rd infusion (Part 1) and 0 to 2 hours post-dose on day 1, and pre-dose days 8 and 15 (Part 2) of Cycle 1

  29. Part 1 & Part 2: Apparent Volume of Distribution (Vz) for Total HuMax-TF (Conjugated and Non-conjugated)

    Vz could not be estimated for Part 1 or Part 2 participants due to insufficient number of samples taken.

    Time frame: 0 to 2 hours post-dose on days 1, 8, 15, +24 hrs 1st infusion, +24 hrs 3rd infusion, +72 hrs 3rd infusion, +168 hrs 3rd infusion (Part 1) and 0 to 2 hours post-dose on day 1, and pre-dose days 8 and 15 (Part 2) of Cycle 1

  30. Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Total HuMax-TF (Conjugated and Non-conjugated)

    Data is only available for Part 1, for Part 2, inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.

    Time frame: Before infusion on Day 1, 8 and 15 of Cycle 1

  31. Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  32. Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)

    Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

    Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1

  33. Part 1: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  34. Part 2: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)

    Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

    Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1

  35. Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)

    Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

  36. Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)

    Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

    Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1

  37. Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Free Toxin (MMAE)

    Data is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.

    Time frame: Before infusion on Day 1, 8 and 15 of Cycle 1

  38. Part 1: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result

    Time frame: Baseline to end of follow-up; maximum follow-up was 24 weeks

  39. Part 2: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  40. Part 1: Number of Patients Who Experienced Anti-tumor Activity Measured by Tumor Shrinkage

    Time frame: Baseline to end of trial (Part 1), up to 72 weeks

  41. Part 2: Anti-tumor Activity Measured by Percentage of Change in Sum of Lesion Measurements

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  42. Part 1: Response Evaluation Based on PSA (Prostate Specific Antigen [Prostate Cancer]): Percentage Change From Baseline to End of Study

    Time frame: Baseline to end of follow-up; maximum follow-up was 24 weeks

  43. Part 1: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study

    Time frame: Baseline to end of follow-up; maximum follow-up was 24 weeks

  44. Part 2: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study

    Time frame: Baseline to end of trial (Part 2), up to 36 week

  45. Part 1: Best Overall Response (OR)

    Best OR (by investigators assessment) was the best response recorded from the start of the treatment until disease progression or death. Complete response: the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. Based on non-target lesions, complete response was defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\< 10 mm short axis). Partial response (PR): ≥ 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Based on non-target lesions, stable disease was defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

    Time frame: Baseline to end of trial (Part 1), up to 72 weeks

  46. Part 2: Best Overall Response (OR)

    Best OR (by investigators assessment) was the best response recorded from the start of the treatment until disease progression or death. Complete response: the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. Based on non-target lesions, complete response was defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\< 10 mm short axis). Partial response (PR): ≥ 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs. Stable Disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Based on non-target lesions, stable disease was defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  47. Part 1: Number of Participants Who Experienced Disease Control

    Participants were defined as having disease control at a specific time point if they had an evaluation of complete response (CR) or partial response (PR) at the time point (with a window of +/- 7 days) or had an evaluation of stable disease (SD), PR or CR at any point from the time point minus 7 days or later.

    Time frame: 6, 12, 24 and 36 weeks post first infusion (Part 1)

  48. Part 2: Number of Participants Who Experienced Disease Control

    Participants were defined as having disease control at a specific time point if they had an evaluation of complete response (CR) or partial response (PR) at the time point (with a window of +/- 7 days) or had an evaluation of stable disease (SD), PR or CR at any point from the time point minus 7 days or later.

    Time frame: 6, 12, 24 and 36 weeks post first infusion (Part 2)

  49. Part 1: Progression Free Survival (PFS)

    Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.

    Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks

  50. Part 2: Progression Free Survival (PFS)

    Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

  51. Part 1: Duration of Response

    Duration of response was defined as as the number of days from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the date of first progressive disease (PD) or death.

    Time frame: Baseline to end of trial (Part 1), up to 72 weeks

  52. Part 2: Duration of Response

    Duration of response was defined as as the number of days from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the date of first progressive disease (PD) or death.

    Time frame: Baseline to end of trial (Part 2), up to 36 weeks

07

Results

Posted Mar 12, 2019

Participant flow

For the Dose Escalation, participants took part in the trial at 3 sites located in Denmark, the United Kingdom (UK), and the United States (USA) from 30 Nov 2015 until 10 Feb 2017. Cohort Expansion trial was performed at 10 sites located in Belgium, UK, Denmark, and the USA from 16 Feb 2016 until the last participant visit on 13 Dec 2017.

Part 1: Dose Level 1 (Weeks 1-16)
Participant flow — Part 1: Dose Level 1 (Weeks 1-16)
MilestonePart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Started30000000
Completed00000000
Not completed30000000
Withdrew: Disease progression20000000
Withdrew: Adverse event10000000
Part 1: Dose Level 2 (Week 17-48)
Participant flow — Part 1: Dose Level 2 (Week 17-48)
MilestonePart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Started06000000
Completed00000000
Not completed06000000
Withdrew: Patient choice01000000
Withdrew: Investigator judgment02000000
Withdrew: Disease progression02000000
Withdrew: Miscellaneous01000000
Part 2: Cohort Expansion
Participant flow — Part 2: Cohort Expansion
MilestonePart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Started001131513
Completed00000100
Not completed001131413
Withdrew: Patient choice00100010
Withdrew: Disease progression00321403
Withdrew: Adverse event00610000
Withdrew: Death00100000

Outcome measures

PrimaryPart 1: Number of Participants Who Experience at Least One Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Experience at Least One Adverse Event (AE)
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants Who Experience at Least One Adverse Event (AE)36
PrimaryPart 2: Number of Participants Who Experience at Least One Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Experience at Least One Adverse Event (AE)
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants Who Experience at Least One Adverse Event (AE)1131503
PrimaryPart 1: Number of Participants Who Experienced at Least One or More Serious Adverse Event (SAE)

A SAE is defined as an AE that met one or more of the following criteria/outcomes which were classified as serious: Required inpatient hospitalization or prolongation of existing hospitalization. Resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. Was a congenital anomaly/birth defect. Medically important determined by the investigator. Resulted in death. Was life-threatening.

Time frame:
Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Experienced at Least One or More Serious Adverse Event (SAE)
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants Who Experienced at Least One or More Serious Adverse Event (SAE)12
PrimaryPart 2: Number of Participants Reporting One or More Serious Adverse Events (SAE)

A SAE is defined as an AE that met one or more of the following criteria/outcomes which were classified as serious: Required inpatient hospitalization or prolongation of existing hospitalization. Resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. Was a congenital anomaly/birth defect. Medically important determined by the investigator. Resulted in death. Was life-threatening.

Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants Reporting One or More Serious Adverse Events (SAE)
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants Reporting One or More Serious Adverse Events (SAE)920201
PrimaryPart 1: Number of Participants Reporting One or More Infusion-related Adverse Events

An infusion-related adverse event (AE) was defined as an AE occurring during infusion where the onset date and time of the event occurred within infusion time (+24 hours), and the event was judged as related to tisotumab vedotin by the investigator.

Time frame:
Day 1, Day 8 & Day 15 (+1 day) until end of treatment (Part 1), approximately 48 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Reporting One or More Infusion-related Adverse Events
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants Reporting One or More Infusion-related Adverse Events24
PrimaryPart 2: Number of Participants Reporting One or More Infusion-related Adverse Events

An infusion-related adverse event (AE) was defined as an AE occurring during infusion where the onset date and time of the event occurred within infusion time (+24 hours), and the event was judged as related to tisotumab vedotin by the investigator.

Time frame:
Day 1, Day 8 & Day 15 (+1 day) until end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants Reporting One or More Infusion-related Adverse Events
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants Reporting One or More Infusion-related Adverse Events421101
PrimaryPart 1: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events

A CTCAE AE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator.

Time frame:
Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events13
PrimaryPart 2: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events

A CTCAE AE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator.

Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events1020301
PrimaryPart 1: Number of Participants Reporting One or More Treatment-related Adverse Events

A treatment-related AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; which has a causal relationship with the treatment.

Time frame:
Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Reporting One or More Treatment-related Adverse Events
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants Reporting One or More Treatment-related Adverse Events36
PrimaryPart 2: Number of Participants Reporting One or More Treatment-related Adverse Events

A treatment-related AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; which has a causal relationship with the treatment.

Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events931503
SecondaryPart 1: Number of Participants With Markedly Abnormal Laboratory Values

The number of participants with any markedly abnormal standard safety laboratory values collected throughout study. Markedly abnormal laboratory values are defined as any grade \>=3 laboratory abnormality events.

Time frame:
Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Markedly Abnormal Laboratory Values
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants With Markedly Abnormal Laboratory Values06
SecondaryPart 2: Number of Participants With Markedly Abnormal Laboratory Values

The number of participants with any markedly abnormal standard safety laboratory values collected throughout study. Markedly abnormal laboratory values are defined as any grade \>=3 laboratory abnormality events.

Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Markedly Abnormal Laboratory Values
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants With Markedly Abnormal Laboratory Values520313
SecondaryPart 1: Number of Participants Who Experienced a Skin Rash
Time frame:
Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Experienced a Skin Rash
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants Who Experienced a Skin Rash04
SecondaryPart 2: Number of Participants Who Experienced a Skin Rash
Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Experienced a Skin Rash
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants Who Experienced a Skin Rash201101
SecondaryPart 1: Number of Participants Who Experienced a Bleeding Event
Time frame:
Baseline to end of trial (Part 1), up to 72 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Experienced a Bleeding Event
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants Who Experienced a Bleeding Event35
SecondaryPart 2: Number of Participants Who Experienced a Bleeding Event
Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Experienced a Bleeding Event
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants Who Experienced a Bleeding Event731502
SecondaryPart 1: Number of Participants Who Experienced a Neuropathy Event
Time frame:
Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Experienced a Neuropathy Event
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants Who Experienced a Neuropathy Event13
SecondaryPart 2: Number of Participants Who Experienced a Neuropathy Event
Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Experienced a Neuropathy Event
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants Who Experienced a Neuropathy Event310201
SecondaryPart 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8 and 15, + 24 hours 1st infusion (Day 2), + 24 hours 3rd infusion (Day 16), + 72 hours 3rd infusion (Day 18), + 168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · h*µg/mL
Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
h*µg/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 13336 ± 7.35317 ± 34.6
Cycle 1 Day 1867 ± 17.61328 ± 48.0
Cycle 1 Day 81603 ± 16.22216 ± 11.7
Cycle 1 Day 15789 ± 15.61411 ± 94.2
SecondaryPart 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)

Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

Time frame:
Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Reported as:
Geometric mean · h*µg/mL
Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
h*µg/mLPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Cycle 12267 ± 24.81755 ± 19.1————
Cycle 1 Dose 11889 ± 29.31412 ± 11.9————
Cycle 1 Dose 2150 ± 56.2123 ± 85.4————
Cycle 1 Dose 3410 ± 26.4204 ± 71.3————
SecondaryPart 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Tisotumab Vedotin (HuMax-TF-ADC)

Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase.

Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8 and 15, + 24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · h*µg/mL
Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Tisotumab Vedotin (HuMax-TF-ADC)
h*µg/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Tisotumab Vedotin (HuMax-TF-ADC)920 ± 3.61106 ± 21.3
SecondaryPart 1: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · µg/mL
Part 1: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
µg/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 121.2 ± 14.530.7 ± 10.1
Cycle 1 Day 120.2 ± 17.928.7 ± 12.1
Cycle 1 Day 820.9 ± 14.128.0 ± 8.9
Cycle 1 Day 1519.9 ± 11.826.8 ± 21.6
SecondaryPart 2: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)

Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

Time frame:
Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Reported as:
Geometric mean · µg/mL
Part 2: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
µg/mLPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Cycle 128.2 ± 34.519.5 ± 17.6————
Cycle 1 Dose 128.2 ± 34.519.5 ± 17.6————
Cycle 1 Dose 21.00 ± 42.01.13 ± 112.2————
Cycle 1 Dose 33.85 ± 24.51.85 ± 77.6————
SecondaryPart 1: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · hours
Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
hoursPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 15.864 ± 172.0225.061 ± 166.177
Cycle 1 Day 10.747 ± 11.5470.873 ± 79.228
Cycle 1 Day 80.717 ± 0.0000.846 ± 86.481
Cycle 1 Day 151.141 ± 81.0751.084 ± 73.110
SecondaryPart 2: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)

Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

Time frame:
Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Reported as:
Geometric mean · hours
Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
hoursPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Cycle 10.75 ± 68.490.58 ± 22.85————
Cycle 1 Dose 10.75 ± 68.490.58 ± 22.85————
Cycle 1 Dose 2165.06 ± 75.01106.93 ± 55.38————
Cycle 1 Dose 371.23 ± 24.3580.37 ± 20.24————
SecondaryPart 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Tisotumab Vedotin (HuMax-TF-ADC)

Data is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.

Time frame:
Before infusion of Day 1, 8 and 15 of Cycle 1
Reported as:
Geometric mean · ng/mL
Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Tisotumab Vedotin (HuMax-TF-ADC)
ng/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 1 Day 130.0 ± 030.0 ± 0
Cycle 1 Day 8797.3 ± 22.11328.5 ± 191.8
Cycle 1 Day 15912.1 ± 23.7989.0 ± 44.3
SecondaryPart 1: Terminal Phase Elimination Half-life (T1/2) for Tisotumab Vedotin (HuMax-TF-ADC)

Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore t1/2 could not be determined.

Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · hours
Part 1: Terminal Phase Elimination Half-life (T1/2) for Tisotumab Vedotin (HuMax-TF-ADC)
hoursPart 1: Dose Escalation: Cohort 1 3q4wk 0.9mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Terminal Phase Elimination Half-life (T1/2) for Tisotumab Vedotin (HuMax-TF-ADC)40.45 ± 24.7848.15 ± 16.47
SecondaryPart 1: Total Clearance (CL) of Tisotumab Vedotin (HuMax-TF-ADC)

Data is only available for Part 1, for Part 2 inadequate pharmacokinetic samples were collected after the third dose to define a terminal phase, and therefore CL could not be determined.

Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · mL/h/kg
Part 1: Total Clearance (CL) of Tisotumab Vedotin (HuMax-TF-ADC)
mL/h/kgPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Total Clearance (CL) of Tisotumab Vedotin (HuMax-TF-ADC)0.979 ± 3.5611.085 ± 21.476
SecondaryPart 1: Apparent Volume of Distribution (Vz) for Tisotumab Vedotin (HuMax-TF-ADC)

Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore Vz could not be determined.

Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · mL/kg
Part 1: Apparent Volume of Distribution (Vz) for Tisotumab Vedotin (HuMax-TF-ADC)
mL/kgPart 1: Dose Escalation: Cohort 1 3q4wk 0.9mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Apparent Volume of Distribution (Vz) for Tisotumab Vedotin (HuMax-TF-ADC)66.75 ± 6.6775.37 ± 14.89
SecondaryPart 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · h*µg/mL
Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
h*µg/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 13916 ± 7.35573 ± 15.0
Cycle 1 Day 11058 ± 15.01530 ± 34.7
Cycle 1 Day 81750 ± 16.22460 ± 8.5
Cycle 1 Day 151012 ± 25.71426 ± 28.6
SecondaryPart 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)

Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

Time frame:
Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Reported as:
Geometric mean · h*µg/mL
Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
h*µg/mLPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Cycle 12660 ± 20.01948 ± 35.2————
Cycle 1 Dose 11980 ± 24.5460 ± 84.5————
Cycle 1 Dose 2299 ± 55.0192 ± 80.9————
Cycle 1 Dose 3679 ± 25.7291 ± 89.9————
SecondaryPart 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Total HuMax-TF (Conjugated and Non-conjugated)

Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase.

Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · h*µg/mL
Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Total HuMax-TF (Conjugated and Non-conjugated)
h*µg/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Total HuMax-TF (Conjugated and Non-conjugated)1268 ± 14.41594 ± 24.6
SecondaryPart 1: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · µg/mL
Part 1: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
µg/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 122.1 ± 9.131.7 ± 11.9
Cycle 1 Day 120.3 ± 14.330.2 ± 34.7
Cycle 1 Day 821.0 ± 6.329.2 ± 6.6
Cycle 1 Day 1520.9 ± 12.029.2 ± 16.2
SecondaryPart 2: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)

Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

Time frame:
Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Reported as:
Geometric mean · µg/mL
Part 2: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
µg/mLPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Cycle 127.5 ± 36.420.6 ± 18.6————
Cycle 1 Dose 127.5 ± 36.420.6 ± 18.6————
Cycle 1 Dose 22.00 ± 41.61.91 ± 105.0————
Cycle 1 Dose 36.39 ± 24.63.68 ± 66.1————
SecondaryPart 1: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · hours
Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
hoursPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 136.445 ± 99.47414.003 ± 117.534
Cycle 1 Day 10.747 ± 11.5470.893 ± 66.752
Cycle 1 Day 80.717 ± 00.869 ± 78.568
Cycle 1 Day 150.727 ± 4.7840.896 ± 78.665
SecondaryPart 2: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)

Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

Time frame:
Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Reported as:
Geometric mean · hours
Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
hoursPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Cycle 10.86 ± 73.610.58 ± 22.85————
Cycle 1 Dose 10.86 ± 73.610.58 ± 22.85————
Cycle 1 Dose 2165.06 ± 75.01106 ± 55.38————
Cycle 1 Dose 371.23 ± 24.3580.37 ± 20.24————
SecondaryPart 1: Terminal Phase Elimination Half-life (T1/2) for Total HuMax-TF (Conjugated and Non-conjugated)

Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore t1/2 could not be determined.

Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · hours
Part 1: Terminal Phase Elimination Half-life (T1/2) for Total HuMax-TF (Conjugated and Non-conjugated)
hoursPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Terminal Phase Elimination Half-life (T1/2) for Total HuMax-TF (Conjugated and Non-conjugated)49.56 ± 17.3549.34 ± 19.18
SecondaryPart 1 and Part 2: Total Clearance (CL) of Total HuMax-TF (Conjugated and Non-conjugated)

CL could not be estimated for Part 1 or Part 2 participants due to insufficient number of samples taken.

Time frame:
0 to 2 hours post-dose on days 1, 8, 15, +24 hrs 1st infusion, +24 hrs 3rd infusion, +72 hrs 3rd infusion, +168 hrs 3rd infusion (Part 1) and 0 to 2 hours post-dose on day 1, and pre-dose days 8 and 15 (Part 2) of Cycle 1

No measurements were reported for this outcome.

SecondaryPart 1 & Part 2: Apparent Volume of Distribution (Vz) for Total HuMax-TF (Conjugated and Non-conjugated)

Vz could not be estimated for Part 1 or Part 2 participants due to insufficient number of samples taken.

Time frame:
0 to 2 hours post-dose on days 1, 8, 15, +24 hrs 1st infusion, +24 hrs 3rd infusion, +72 hrs 3rd infusion, +168 hrs 3rd infusion (Part 1) and 0 to 2 hours post-dose on day 1, and pre-dose days 8 and 15 (Part 2) of Cycle 1

No measurements were reported for this outcome.

SecondaryPart 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Total HuMax-TF (Conjugated and Non-conjugated)

Data is only available for Part 1, for Part 2, inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.

Time frame:
Before infusion on Day 1, 8 and 15 of Cycle 1
Reported as:
Geometric mean · ng/mL
Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Total HuMax-TF (Conjugated and Non-conjugated)
ng/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 1 Day 1150.0 ± 0.0150.0 ± 0.0
Cycle 1 Day 81273.1 ± 23.41252.2 ± 53.3
Cycle 1 Day 151625.1 ± 24.41863.8 ± 46.6
SecondaryPart 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)
Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · h*ng/mL
Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)
h*ng/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 1885 ± 27.1968 ± 59.7
Cycle 1 Day 1185 ± 48.1185 ± 75.3
Cycle 1 Day 8180 ± 14.1236 ± 75.5
Cycle 1 Day 15506 ± 25.3520 ± 51.3
SecondaryPart 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)

Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

Time frame:
Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Reported as:
Geometric mean · h*ng/mL
Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)
h*ng/mLPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Cycle 1920 ± 74.51049 ± 89.4————
Cycle 1 Dose 1439 ± 69.3393 ± 100.0————
Cycle 1 Dose 2378 ± 121.3366 ± 77.9————
Cycle 1 Dose 3713 ± 49.9494 ± 121.7————
SecondaryPart 1: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)
Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · ng/mL
Part 1: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)
ng/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 12.76 ± 23.72.88 ± 52.4
Cycle 1 Day 11.46 ± 54.71.38 ± 78.4
Cycle 1 Day 81.18 ± 19.81.54 ± 75.4
Cycle 1 Day 152.76 ± 23.72.88 ± 52.4
SecondaryPart 2: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)

Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

Time frame:
Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Reported as:
Geometric mean · ng/mL
Part 2: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)
ng/mLPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Cycle 13.9 ± 97.03.6 ± 101.4————
Cycle 1 Dose 11.9 ± 110.51.5 ± 80.4————
Cycle 1 Dose 22.47 ± 136.42.50 ± 81.1————
Cycle 1 Dose 33.78 ± 81.63.23 ± 125.0————
SecondaryPart 1: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)
Time frame:
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Reported as:
Geometric mean · hours
Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)
hoursPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 1392.024 ± 3.256373.366 ± 6.290
Cycle 1 Day 144.568 ± 114.56732.001 ± 125.788
Cycle 1 Day 810.354 ± 165.50920.837 ± 106.094
Cycle 1 Day 1554.511 ± 20.42432.537 ± 63.879
SecondaryPart 2: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)

Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).

Time frame:
Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Reported as:
Geometric mean · hours
Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)
hoursPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Cycle 1307.05 ± 36.52410.61 ± 3.82————
Cycle 1 Dose 1160.56 ± 5.66162.19 ± 1.71————
Cycle 1 Dose 2164.82 ± 56.71106.93 ± 55.38————
Cycle 1 Dose 378.37 ± 50.2680.37 ± 20.24————
SecondaryPart 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Free Toxin (MMAE)

Data is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.

Time frame:
Before infusion on Day 1, 8 and 15 of Cycle 1
Reported as:
Geometric mean · pg/mL
Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Free Toxin (MMAE)
pg/mLPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Cycle 1 Day 112.50 ± 012.50 ± 0
Cycle 1 Day 8853.42 ± 22.931061.28 ± 87.81
Cycle 1 Day 151013.22 ± 14.471384.29 ± 83.43
SecondaryPart 1: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result
Time frame:
Baseline to end of follow-up; maximum follow-up was 24 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result00
SecondaryPart 2: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result
Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result000000
SecondaryPart 1: Number of Patients Who Experienced Anti-tumor Activity Measured by Tumor Shrinkage
Time frame:
Baseline to end of trial (Part 1), up to 72 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Patients Who Experienced Anti-tumor Activity Measured by Tumor Shrinkage
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Number of Patients Who Experienced Anti-tumor Activity Measured by Tumor Shrinkage13
SecondaryPart 2: Anti-tumor Activity Measured by Percentage of Change in Sum of Lesion Measurements
Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Mean · percentage of change
Part 2: Anti-tumor Activity Measured by Percentage of Change in Sum of Lesion Measurements
percentage of changePart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Anti-tumor Activity Measured by Percentage of Change in Sum of Lesion Measurements-17.34 ± 43.38832.78 ± 83.933-63.27 ± NA0.74 ± 21.8770 ± NA11.76 ± 27.658
SecondaryPart 1: Response Evaluation Based on PSA (Prostate Specific Antigen [Prostate Cancer]): Percentage Change From Baseline to End of Study
Time frame:
Baseline to end of follow-up; maximum follow-up was 24 weeks
Reported as:
Mean · percentage of change
Part 1: Response Evaluation Based on PSA (Prostate Specific Antigen [Prostate Cancer]): Percentage Change From Baseline to End of Study
percentage of changePart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Response Evaluation Based on PSA (Prostate Specific Antigen [Prostate Cancer]): Percentage Change From Baseline to End of Study23.42 ± 61.68612.97 ± NA
SecondaryPart 1: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study
Time frame:
Baseline to end of follow-up; maximum follow-up was 24 weeks
Reported as:
Mean · percentage of change
Part 1: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study
percentage of changePart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study—186.21 ± NA
SecondaryPart 2: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study
Time frame:
Baseline to end of trial (Part 2), up to 36 week
Reported as:
Mean · percentage of change
Part 2: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study
percentage of changePart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 5 1q3w Ovarian
Part 2: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study-31.75 ± 36.235-32.50 ± NA—
SecondaryPart 1: Best Overall Response (OR)

Best OR (by investigators assessment) was the best response recorded from the start of the treatment until disease progression or death. Complete response: the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. Based on non-target lesions, complete response was defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\< 10 mm short axis). Partial response (PR): ≥ 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Based on non-target lesions, stable disease was defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

Time frame:
Baseline to end of trial (Part 1), up to 72 weeks
Reported as:
Number · participants
Part 1: Best Overall Response (OR)
participantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Complete Response00
Partial Response01
Stable Disease23
Progressive Disease11
Not Evaluable01
SecondaryPart 2: Best Overall Response (OR)

Best OR (by investigators assessment) was the best response recorded from the start of the treatment until disease progression or death. Complete response: the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. Based on non-target lesions, complete response was defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\< 10 mm short axis). Partial response (PR): ≥ 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs. Stable Disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Based on non-target lesions, stable disease was defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Number · participants
Part 2: Best Overall Response (OR)
participantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Complete Response000000
Partial Response311200
Stable Disease300202
Progressive Disease220111
Not Evaluable300000
SecondaryPart 1: Number of Participants Who Experienced Disease Control

Participants were defined as having disease control at a specific time point if they had an evaluation of complete response (CR) or partial response (PR) at the time point (with a window of +/- 7 days) or had an evaluation of stable disease (SD), PR or CR at any point from the time point minus 7 days or later.

Time frame:
6, 12, 24 and 36 weeks post first infusion (Part 1)
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Experienced Disease Control
ParticipantsPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
6 Weeks — Disease Control - Yes23
6 Weeks — Disease Control - No13
12 Weeks — Disease Control - Yes00
12 Weeks — Disease Control - No36
24 Weeks — Disease Control - Yes00
24 Weeks — Disease Control - No36
36 Weeks — Disease Control - Yes00
36 Weeks — Disease Control - No36
SecondaryPart 2: Number of Participants Who Experienced Disease Control

Participants were defined as having disease control at a specific time point if they had an evaluation of complete response (CR) or partial response (PR) at the time point (with a window of +/- 7 days) or had an evaluation of stable disease (SD), PR or CR at any point from the time point minus 7 days or later.

Time frame:
6, 12, 24 and 36 weeks post first infusion (Part 2)
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Experienced Disease Control
ParticipantsPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
6 Weeks — Disease Control - Yes611402
6 Weeks — Disease Control - No520111
12 Weeks — Disease Control - Yes211201
12 Weeks — Disease Control - No920312
24 Weeks — Disease Control - Yes000100
24 Weeks — Disease Control - No1131413
36 Weeks — Disease Control - Yes000000
36 Weeks — Disease Control - No1131513
SecondaryPart 1: Progression Free Survival (PFS)

Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.

Time frame:
Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Reported as:
Median · weeks
Part 1: Progression Free Survival (PFS)
weeksPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Part 1: Progression Free Survival (PFS)11.3 (7.3 to 15.3)NA (7.1 to NA)
SecondaryPart 2: Progression Free Survival (PFS)

Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.

Time frame:
Baseline to end of trial (Part 2), up to 36 weeks
Reported as:
Median · weeks
Part 2: Progression Free Survival (PFS)
weeksPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2: Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
Part 2: Progression Free Survival (PFS)10.7 (2.0 to NA)8.0 (4.3 to NA)22.0 (NA to NA)14.0 (9.1 to NA)5.0 (NA to NA)11.9 (11.0 to 17.1)
SecondaryPart 1: Duration of Response

Duration of response was defined as as the number of days from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the date of first progressive disease (PD) or death.

Time frame:
Baseline to end of trial (Part 1), up to 72 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Duration of Response

Duration of response was defined as as the number of days from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the date of first progressive disease (PD) or death.

Time frame:
Baseline to end of trial (Part 2), up to 36 weeks

No measurements were reported for this outcome.

Adverse events

Collected over Part 1: Dose Escalation: Baseline to follow-up; maximum time of follow-up was 24 weeks. Part 2: Cohort Expansion: Baseline to a maximum of 36 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg0/6 (0%)2/6 (33.3%)6/6 (100%)
Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian1/11 (9.1%)9/11 (81.8%)10/11 (90.9%)
Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical0/3 (0%)2/3 (66.7%)3/3 (100%)
Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian0/1 (0%)0/1 (0%)1/1 (100%)
Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical0/5 (0%)2/5 (40%)5/5 (100%)
Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian0/1 (0%)0/1 (0%)0/1 (0%)
Part 2: Cohort Expansion: Cohort 6 1q3w Cervical0/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
SymblepharonEye disorders0/30/64/111/30/10/50/10/3
DiarrhoeaGastrointestinal disorders0/30/60/110/30/10/50/11/3
ConjunctivitisInfections and infestations1/30/63/111/30/10/50/10/3
DehydrationMetabolism and nutrition disorders0/30/60/111/30/10/50/10/3
GastroenteritisInfections and infestations0/30/60/110/30/10/50/11/3
Colonic pseudo-obstructionGastrointestinal disorders0/30/60/110/30/11/50/10/3
HyponatraemiaMetabolism and nutrition disorders0/31/60/110/30/11/50/10/3
Vaginal haemorrhageReproductive system and breast disorders0/30/60/110/30/11/50/10/3
NauseaGastrointestinal disorders0/31/61/110/30/10/50/10/3
VomitingGastrointestinal disorders0/31/61/110/30/10/50/10/3
Most frequent other events
Showing 10 of 120
Most frequent other events
EventPart 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w Cervical
NauseaGastrointestinal disorders2/32/65/111/31/11/50/10/3
Abdominal painGastrointestinal disorders0/33/64/110/31/13/50/10/3
Lip ulcerationGastrointestinal disorders0/30/60/110/31/10/50/10/3
ConjunctivitisInfections and infestations2/36/65/110/30/13/50/11/3
EpistaxisRespiratory, thoracic and mediastinal disorders3/35/67/111/31/13/50/12/3
Nasal congestionRespiratory, thoracic and mediastinal disorders0/30/61/110/31/11/50/10/3
FatigueGeneral disorders2/32/66/111/31/14/50/12/3
Decreased appetiteMetabolism and nutrition disorders2/33/65/111/31/11/50/10/3
AlopeciaSkin and subcutaneous tissue disorders0/31/65/111/31/13/50/12/3
PruritusSkin and subcutaneous tissue disorders0/31/61/111/31/11/50/10/3

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w CervicalTotal
Adults (18-64 years)03103141325
From 65 to 84 years331001008
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w CervicalTotal
Female14113151329
Male220000004
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w CervicalTotal
Hispanic or Latino001000001
Not Hispanic or Latino36103151332
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w CervicalTotal
American Indian or Alaska Native000000000
Asian011000002
Native Hawaiian or Other Pacific Islander000000000
Black or African American000000000
White35103151331
More than one race000000000
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(participants)Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w CervicalTotal
Belgium0063020213
United States031000004
Denmark220001005
United Kingdom1140121111
Weight
Weight(kg)Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w CervicalTotal
Part 1: Dose Escalation80.0 (76.3 to 80.0)67.5 (48.1 to 85.0)——————74.7 (48.1 to 85.0)
Part 2: Cohort Expansion——66.8 (40.0 to 89.6)55.2 (41.7 to 63.5)57.8 (57.8 to 57.8)72.0 (52.8 to 79.3)96.8 (96.8 to 96.8)65.3 (60.5 to 65.5)64.8 (40.0 to 96.8)
Height
Height(cm)Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w CervicalTotal
Part 1: Dose Escalation171.0 (168.0 to 171.4)162.0 (156.0 to 175.0)——————168.0 (156.0 to 175.0)
Part 2: Cohort Expansion——159.0 (154.0 to 174.0)157.0 (148.0 to 161.0)160.6 (160.6 to 160.6)168.0 (159.0 to 177.8)170.5 (170.5 to 170.5)161.0 (156.0 to 162.0)160.8 (148.0 to 177.8)
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kgPart 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kgPart 2: Cohort Expansion: Cohort 1 3q4wk OvarianPart 2: Cohort Expansion: Cohort 2 3q4wk CervicalPart 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w OvarianPart 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w CervicalPart 2 Cohort Expansion: Cohort 5 1q3w OvarianPart 2: Cohort Expansion: Cohort 6 1q3w CervicalTotal
Part 1: Dose Escalation27.4 (26.0 to 28.3)25.5 (19.8 to 27.8)——————25.7 (19.8 to 28.3)
Part 2: Cohort Expansion——26.4 (16.9 to 32.5)22.4 (16.1 to 29.0)22.4 (22.4 to 22.4)24.0 (18.7 to 28.5)33.3 (33.3 to 33.3)24.9 (23.3 to 26.9)25.1 (16.1 to 33.3)
08

Study locations

16 sites
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Institut Jules Bordet
    Bruxelles, Brussels 1000, Belgium
  • Universitaire Ziekenhuizen Leuven
    Leuven, Flemish Brabant 3000, Belgium
  • Grand Hôpital de Charleroi
    Charleroi, Hainaut 6000, Belgium
  • CHU de Liège
    Liege, Liège 4000, Belgium
  • CHU UCL Namur - site Godinne
    Yvoir, Namur 5530, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • CHU UCL Namur - Sainte Elisabeth
    Namur, 5000, Belgium
  • Rigshospitalet, Copenhagen University Hospital
    Copenhagen, DK-2100, Denmark
  • Petz Aladár Megyei Oktató Kórház
    Gyor, Gyor-Moson-Sopron 9023, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, Hajdu-Bihar 4032, Hungary
  • Semmelweis Egyetem Onkológiai Központ
    Budapest, 1083, Hungary
  • University College London Hospitals NHS Foundation Trust
    London, England NW1 2PG, United Kingdom
  • Sarah Cannon Cancer Center
    London, England W1G 6AD, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, England M20 4BX, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Dec 2017, 24 months.

Results were first posted in Mar 2019, 1 year 2 months after primary completion.

Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's 24 months is below that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2015
First posted
Sep 16, 2015
StartActual
Nov 30, 2015
Primary completionActual
Dec 13, 2017
CompletionActual
Dec 13, 2017
Results first posted
Mar 12, 2019
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02552121
Lead sponsor
Seagen Inc.
Collaborators
Genmab
Responsible party
Sponsor
First posted
Sep 16, 2015
Start date
Nov 30, 2015
Primary completion
Dec 13, 2017
Completion
Dec 13, 2017
Results posted
Mar 12, 2019
Last update
Apr 8, 2021

Study contacts

Johann de Bono, Professor
principal investigator · The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisotumab vedotin

Start the discussion